Xenetic Biosciences XBIO
NASDAQ XBIO
$2.24 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Xenetic Biosciences (XBIO) Gains from Sales and Divestitures (2014 - 2019)

Updated

Xenetic Biosciences' Gains from Sales and Divestitures came in at $2,000 for FY2019, down 87.0% from $15,437 in FY2018.

Analysis

Xenetic Biosciences (XBIO) Gains from Sales and Divestitures (2014 - 2019) Analysis & Trends

  • The FY2019 figure represents the lowest annual Gains from Sales and Divestitures since FY2014.
  • Per Business Quant, earlier years put Gains from Sales and Divestitures at $15,437 in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Xenetic Biosciences 5.25 Mn -20.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 2,000.00
Sep 30, 2018 15,437.00
Mar 31, 2014 -1.07 Mn
API Access

Xenetic Biosciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=XBIO&period=max&api_key=YOUR_API_KEY